• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep Med . A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity

tetano

Editor, Senior Moderator
Cell Rep Med


. 2024 May 2:101553.
doi: 10.1016/j.xcrm.2024.101553. Online ahead of print. A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity

Chang Liu[SUP] 1 [/SUP], Daming Zhou[SUP] 2 [/SUP], Aiste Dijokaite-Guraliuc[SUP] 3 [/SUP], Piyada Supasa[SUP] 4 [/SUP], Helen M E Duyvesteyn[SUP] 5 [/SUP], Helen M Ginn[SUP] 6 [/SUP], Muneeswaran Selvaraj[SUP] 4 [/SUP], Alexander J Mentzer[SUP] 7 [/SUP], Raksha Das[SUP] 4 [/SUP], Thushan I de Silva[SUP] 8 [/SUP], Thomas G Ritter[SUP] 9 [/SUP], Megan Plowright[SUP] 10 [/SUP], Thomas A H Newman[SUP] 10 [/SUP], Lizzie Stafford[SUP] 9 [/SUP], Barbara Kronsteiner[SUP] 11 [/SUP], Nigel Temperton[SUP] 12 [/SUP], Yuan Lui[SUP] 13 [/SUP], Martin Fellermeyer[SUP] 13 [/SUP], Philip Goulder[SUP] 14 [/SUP], Paul Klenerman[SUP] 15 [/SUP], Susanna J Dunachie[SUP] 16 [/SUP], Michael I Barton[SUP] 17 [/SUP], Mikhail A Kutuzov[SUP] 17 [/SUP], Omer Dushek[SUP] 17 [/SUP]; OPTIC Consortium; Elizabeth E Fry[SUP] 18 [/SUP], Juthathip Mongkolsapaya[SUP] 19 [/SUP], Jingshan Ren[SUP] 20 [/SUP], David I Stuart[SUP] 21 [/SUP], Gavin R Screaton[SUP] 22 [/SUP]



Affiliations
Abstract

BA.2.86, a recently described sublineage of SARS-CoV-2 Omicron, contains many mutations in the spike gene. It appears to have originated from BA.2 and is distinct from the XBB variants responsible for many infections in 2023. The global spread and plethora of mutations in BA.2.86 has caused concern that it may possess greater immune-evasive potential, leading to a new wave of infection. Here, we examine the ability of BA.2.86 to evade the antibody response to infection using a panel of vaccinated or naturally infected sera and find that it shows marginally less immune evasion than XBB.1.5. We locate BA.2.86 in the antigenic landscape of recent variants and look at its ability to escape panels of potent monoclonal antibodies generated against contemporary SARS-CoV-2 infections. We demonstrate, and provide a structural explanation for, increased affinity of BA.2.86 to ACE2, which may increase transmissibility.

Keywords: ACE2 binding; BA.2.65; SARS-CoV-2; antigenic escape; coronavirus; receptor binding; virus evolution; virus structure.

 
Back
Top Bottom